SAB Biotherapeutics Inc Cash Flow Quality Index
SAB Biotherapeutics Inc cash flow quality index. SAB Biotherapeutics Inc (SABS) has a Cash Flow Quality Index of -2.44x as of September 2025. Operating cash flow of $-13.05 Million is below net income of $5.34 Million, suggesting accrual-heavy earnings not yet converted to cash. See SAB Biotherapeutics Inc (SABS) flexibility index to measure the company's free cash flow as a share of total liabilities.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of SAB Biotherapeutics Inc (2020–2025)
Cash flow quality index of SAB Biotherapeutics Inc from 2020 to 2025. Historical Cash Flow Quality Index for SAB Biotherapeutics Inc across 2 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore SAB Biotherapeutics Inc debt service capacity to assess how comfortably operating cash covers total debt obligations.
SAB Biotherapeutics Inc Cash Flow Quality Index by Year (2020–2025)
SAB Biotherapeutics Inc cash flow quality index by year from 2020 to 2025. Year-by-year earnings quality comparison for SAB Biotherapeutics Inc. For the full cash flow conversion analysis, see SAB Biotherapeutics Inc cash flow conversion.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | -3.37x | $-44.78 Million | $13.27 Million | ▼ -778.3% |
| 2020 | 0.50x | $10.00 Million | $20.12 Million | — |